🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

16+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 16 of 16 recruiting trials for “Myotonic dystrophy”

Phase 2RecruitingNCT07220603 ↗

An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

🏥 PepGen Inc📍 3 sites📅 Started Dec 2025View details ↗
RecruitingNCT06747884 ↗

Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension

👨‍⚕️ Nicholas Johnson, MD, MSCI, FAAN, Virginia Commonwealth University📍 1 site📅 Started Jun 2025View details ↗
RecruitingNCT07385443 ↗

The Spanish National Registry for Myotonic Dystrophy Type 1

👨‍⚕️ Gisela Nogales Gadea, Ph.D., Germans Trias i Pujol Research Institute📍 8 sites📅 Started Jun 2025View details ↗
RecruitingNCT07362875 ↗

Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy

👨‍⚕️ Araya Puwanant, MD, Wake Forest University Health Sciences📍 1 site📅 Started May 2025View details ↗
NARecruitingNCT06809049 ↗

Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)

🏥 Hanns Lochmuller📍 1 site📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06667453 ↗

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

🏥 PepGen Inc📍 8 sites📅 Started Dec 2024View details ↗
Phase 3RecruitingNCT05532813 ↗

Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)

👨‍⚕️ Pascal LAFORÊT, MD, PhD, Neurology Department, Raymond Poincaré Hospital, APHP📍 1 site📅 Started Nov 2024View details ↗
Phase 1, PHASE2RecruitingNCT06300307 ↗

Study of ATX-01 in Participants With DM1

🏥 ARTHEx Biotech S.L.📍 12 sites📅 Started Oct 2024View details ↗
NARecruitingNCT06316778 ↗

Pelvic Floor Muscle Training for Women with Myotonic Dystrophy

🏥 Université de Sherbrooke📍 1 site📅 Started Mar 2024View details ↗
Phase 1, PHASE2RecruitingNCT06138743 ↗

Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

🏥 Arrowhead Pharmaceuticals📍 11 sites📅 Started Mar 2024View details ↗
RecruitingNCT06378216 ↗

Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]

🏥 IRCCS Eugenio Medea📍 1 site📅 Started Sep 2022View details ↗
RecruitingNCT05224778 ↗

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

👨‍⚕️ Nicholas E. Johnson, MD, Virginia Commonwealth University📍 5 sites📅 Started Aug 2022View details ↗
Phase 2, PHASE3RecruitingNCT05004129 ↗

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

👨‍⚕️ Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM, AMO Pharma📍 14 sites📅 Started Aug 2021View details ↗
Enrolling by InvitationNCT06101940 ↗

A Multicenter Phenotype-Genotype Analysis of DM1 Patients in China

👨‍⚕️ Chongbo Zhao, PhD, Huashan Hospital📍 22 sites📅 Started Aug 2021View details ↗
RecruitingNCT05020002 ↗

Extracellular RNA Biomarkers of Myotonic Dystrophy

👨‍⚕️ Thurman M. Wheeler, MD, Massachusetts General Hospital📍 3 sites📅 Started Dec 2020View details ↗
RecruitingNCT03981575 ↗

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

👨‍⚕️ Nicholas Johnson, MD, Virginia Commonwealth University📍 17 sites📅 Started Jan 2019View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →